THE UNIVERSITY OF RHODE ISLAND

University of Rhode Island DigitalCommons@URI

Pharmacy Practice Faculty Publications

Pharmacy Practice

2014

Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin Against Biofilm-Forming *Enterococcus faecalis* or *E. faecium* in an *In Vitro* Pharmacodynamic Model Using Simulated Endocardial Vegetations and an *In Vivo* Survival Assay Using *Galleria mellonella* Larvae

Megan K. Luther *University of Rhode Island* Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs <u>Marios Arvanitis</u>

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use

This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use.

Citation/Publisher Attribution

Luther M. K., Arvanitis M., Mylonakis E., & LaPlante K. L. (2014). Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. *Antimicrobial Agents and Chemotherapy*, 58(8), 4612-4620. doi: 10.1128/AAC.02790-13

Available at: http://dx.doi.org/10.1128/AAC.02790-13

This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors

Megan K. Luther, Marios Arvanitis, Eleftherios Mylonakis, and Kerry L. LaPlante

Running Title: Enterococcal Infective Endocarditis

Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-forming *Enterococcus faecalis* or *E. faecium* in an In Vitro Pharmacodynamic Model using Simulated Endocardial Vegetations and In Vivo Survival Assay using *Galleria mellonella* Larvae

May 12, 2014

Megan K. Luther^{1,2}, Marios Arvanitis^{3,4}, Eleftherios Mylonakis^{3,4}, Kerry L. LaPlante^{1,2,3*}

University of Rhode Island, Department of Pharmacy Practice¹, Rhode Island Infectious Diseases (RIID) Research Program Laboratory, Providence Veterans Affairs Medical Center², Division of Infectious Diseases, Warren Alpert Medical School of Brown University³, Rhode Island Hospital⁴, Providence, RI

*Corresponding Author: Kerry L. LaPlante, Pharm.D. Associate Professor of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881, office: 401-874-5560; e-mail: KerryLaPlante@uri.edu

Abstract Count: 245

Key words (MESH): biofilm, daptomycin, gentamicin, linezolid, rifampin, *Enterococcus faecalis, Enterococcus faecium,* vancomycin resistance, and *Galleria mellonella*

1 Abstract Enterococci are the third most frequent cause of infective endocarditis. A high-2 inoculum stationary phase in vitro pharmacodynamic model with simulated endocardial 3 vegetations was used to simulate human pharmacokinetics of daptomycin 6 or 10mg/kg/day, 4 or linezolid 600mg g12h alone and in combination with gentamicin 1.3mg/kg g12h, rifampin 5 300mg q8h or 900mg q24h. Biofilm-forming vancomycin-susceptible Enterococcus faecalis 6 and vancomycin-resistant E. faecium (VRE) were tested. At 24, 48 and 72h, all daptomycin-7 containing regimens demonstrated significantly more activity (decline in CFU/g) than any 8 linezolid-containing regimen against biofilm-forming *E. faecalis*. The addition of gentamicin 9 to daptomycin (6 and 10mg/kg) in the first 24 hours significantly improved the bactericidal 10 activity. In contrast, addition of rifampin delayed the bactericidal activity of daptomycin 11 against *E. faecalis*; and against VRE, antagonized all regimens at 24h. Also, against VRE, 12 addition of gentamicin to linezolid at 72h improved activity and was bactericidal. Rifampin 13 significantly antagonized the activity of linezolid against VRE at 72h. In in vivo Galleria 14 mellonella survival assays, linezolid and daptomycin improved survival. Daptomycin 10mg/kg 15 improved survival significantly over linezolid against E. faecalis. Addition of gentamicin 16 improved efficacy of daptomycin against *E. faecalis* and linezolid and daptomycin against 17 VRE. We conclude that in enterococcal infection models, daptomycin has more activity than 18 linezolid alone. Against biofilm-forming *E. faecalis*, the addition of gentamicin in the first 24h 19 causes the most rapid decline in CFU/g. Of interest, addition of rifampin delayed or 20 antagonized activity of daptomycin against biofilm-forming *E. faecalis* and VRE respectively 21 in the first 24h.

22

23

Introduction.

24 Despite major advances in medicine and surgery, infective endocarditis (IE) remains a 25 concerning disease associated with considerable morbidity and mortality.(1) Bacterial causes 26 of IE and bacteremia have changed over the past few decades and now streptococci. 27 staphylococci, and enterococci have emerged as the major pathogens.(2) Among these, 28 Enterococcus has become the most challenging to treat. Barriers in treating these infections 29 include the need for multiple agents to demonstrate bactericidal activity and microbiological 30 cure (1); biofilm production among these bacteria (3, 4); and resistance to the mainstays of 31 therapy (i.e., ampicillin, penicillin, and vancomycin) (5). Biofilm production in enterococci is 32 common in E. faecalis, with worldwide rates reported between 26-100%, and 93% reported 33 in the US.(3) The 2005 American Heart Association recommendations for drug-resistant 34 enterococcal IE include linezolid and guinupristin-dalfopristin, which are both bacteriostatic 35 against enterococci.(1).

36 Daptomycin, at high doses, demonstrates bactericidal activity against enterococci in 37 other types of infection, and against S. aureus in endocarditis.(6, 7) This is due to 38 daptomycin's mechanism of action as it disrupts the cell-membrane potential and is growth 39 phase independent.(8) There is promising data demonstrating in vitro synergy with 40 gentamicin and daptomycin combination therapy against VRE (9-13), and case reports also 41 support these findings.(11, 14, 15) Therefore, the addition of gentamicin, a ribosomal active 42 agent may provide a synergistic approach in VRE IE infections. Additionally, since E. 43 faecalis often produce biofilm, (3) it is of interest to evaluate daptomycin's activity in 44 combination with rifampin. (16-18) Finally, since daptomycin demonstrates concentration-45 dependent killing, evaluation of approved doses (6mg/kg) and higher doses (10mg/kg) may 46 result in increased activity and resistance prevention, (19) as there is established efficacy in 47 other infection types (20) with appropriate safety data. (21)

- 3 -

We therefore evaluated the in vitro activity of daptomycin and linezolid alone and in combination with gentamicin or rifampin against enterococci in an in vitro model with sequestered high inoculum stationary phase infection using simulated endocardial vegetations (SEV).(20, 22, 23) We also tested these regimens in an in vivo survival assay using *Galleria mellonella* larvae. We used a vancomycin-susceptible biofilm-producing *E. faecalis* and a vancomycin-resistant *E. faecium*. We also evaluated biofilm production of these isolates.

55 MATERIALS AND METHODS

56 **Bacterial strains.** We evaluated a vancomycin-susceptible, ampicillin-susceptible *E.* 57 *faecalis,* ATCC 29212 (also gentamicin-susceptible and rifampin-susceptible) and a 58 vancomycin- resistant (VRE) *E. faecium* clinical isolate from the Providence Veterans Affairs 59 Medical Center (also penicillin-resistant, gentamicin-susceptible, and rifampin resistant). Both 60 isolates were linezolid and daptomycin susceptible.

Antimicrobial agents. Linezolid (lot# 11C03U04, 10H10Z16; Pfizer, Inc.; NY) was
 obtained commercially, and daptomycin was obtained from Cubist Pharmaceuticals, Inc.,
 (Lexington, MA). Rifampin (lot 085K1929) and gentamicin (lot 050K03421, 097K06887V)
 were purchased from Sigma Chemical Company (St. Louis, MO). Stock solutions of each
 antibiotic were freshly prepared at the beginning of each week and kept frozen at -4°C.

66 Medium. As previously described, Mueller-Hinton broth (Becton Dickinson, Sparks, MD) supplemented with calcium and adjusted to physiologic conditions of 50 mg/L calcium 67 68 chloride (ionized Ca; 1.03-1.23 mmol/L) and 12.5 mg/L magnesium was used for all 69 susceptibility analyses and in vitro pharmacodynamic analyses.(24) Bacto Tryptic Soy Broth 70 (TSB; Becton Dickinson) supplemented with 1% glucose and 50mg/L calcium chloride was 71 used to optimize biofilm production in the biofilm assay. (25, 26) Colony counts were 72 determined using Tryptic Soy Agar (TSA, Difco, Becton Dickinson). For the in vivo study, 73 strains were grown overnight at 30 °C in brain heart infusion (BHI) with agitation. Inoculum 74 was confirmed by plating serial dilutions on BHI agar.

Susceptibility. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentration (MBC) testing was determined at both standard ($\sim 10^6$ CFU/mL) and high inoculum ($\sim 10^9$ CFU/mL) in triplicate using microbroth dilution according to CLSI methods.(27). All samples were incubated at 35° C for 24 hours prior to interpretation of results.

- 5 -

80 Biofilm Formation. In growth conditions (media; see above) that optimize biofilm 81 production in Enterococcus, quantification of biofilm formation was conducted using the 82 microtiter plate assay first described by Christensen et al. (28) and modified as follows. 83 Briefly, stationary cultures of an overnight growth of the Enterococcal strains (1% vol/vol) were diluted into fresh cation- and glucose-supplemented TSB. The inoculated medium was 84 85 dispensed into wells of sterile flat-bottom 96-well polystyrene tissue culture plates (Costar no. 86 3596; Corning Inc., Corning, NY, USA). Biofilm production in Enterococcus has been linked 87 to several genes including, fsr, gelE, and sprE.(29) Previous findings support that expression 88 of these genes were found at 24h of growth.(29) We examined two sets of plates, incubated at 35°C a minimum of 24h and 48h, respectively. The attached bacteria was then fixed and 89 90 stained with crystal violet. After drying, the optical density (OD) of stained adherent bacterial 91 films was read using a µQuant[™] Microplate Spectrophotometer microtiter dish reader (Bio-92 Tek Instruments, Inc. Winooski, Vermont, USA.). The optical density (OD) of bacterial films 93 were classified into the following categories: no biofilm production, weakly (+), moderately 94 (++), or strongly (+++) adherent, based upon the ODs of bacterial films (30). The test was 95 carried out in triplicate. The results were averaged.

96 In vitro pharmacodynamic infection model with Simulated Endocardial 97 **Vegetations (SEVs).** As previously described, organism stocks containing approximately 10¹⁰ CFU/mL were prepared by inoculating 5mL test tubes of normal saline with colonies 98 SEVs containing 10⁹ 99 harvested from fresh overnight growth on TSA.(20, 22, 24, 31, 32) 100 CFU/g were prepared by combining 0.05mL of the organism suspension with 0.4mL of 101 human cryoprecipitate antihemolytic factor (AHF) from volunteer donors (Rhode Island Blood 102 Bank, Providence, RI), 0.05mL of aprotinin suspension, and 0.025 mL of platelet suspension 103 (platelets mixed with normal saline, 250,000 to 500,000 platelets per clot) in 1.5 mL 104 eppendorf tubes. Bovine thrombin (5,000 units/mL, 50 µL), was added to each tube after

- 6 -

insertion of a sterile monofilament line into the mixture. The resultant SEVs were removed
 from eppendorf tubes with a sterile 21-gauge needle and introduced into the model. This
 methodology results in SEVs containing approximately 3-3.5 g/dL of albumin and 6.8-7.4
 g/dL of total protein (22).

109 In vitro pharmacodynamic infection model. An in vitro infection model consisting 110 of a 250 mL one-compartment glass apparatus with ports where the SEVs are suspended, 111 was utilized for all simulations. The apparatus was pre-filled with media and antibiotics were 112 administered as boluses over a 72-hour period into the central compartment via an injection The models were placed in a 35°C water bath throughout the procedure with a 113 port. 114 magnetic stir bar for thorough mixing of the drug in the model. Fresh media was 115 continuously supplied and removed from the model via a peristaltic pump (Masterflex, Cole-116 Parmer Instrument Company, Chicago, IL USA) set to simulate the half-lives of the 117 antibiotics. Two SEVs were removed from each model at 0, 4, 8, 24, 32, 48, 56 and 72 118 hours. Once removed, SEVs were then immediately homogenized in trypsin, plated onto 119 TSA, and incubated at 35°C for 24 hours before colony count enumeration. This method 120 results in a lower limit of detection of 2.0 log₁₀ CFU/g (23). Antimicrobial carryover was 121 minimized by serial dilution (10-10,000) of plated samples in conjunction with vacuum 122 filtration, when necessary, where samples were washed through a 0.22 µm filter with sterile These filters were then plated onto TSA and incubated at 35° C for 24 hours. 123 water. 124 Colonies were counted on filter paper; the limit of detection is $1.0 \log_{10} CFU/g$.

Daptomycin was administered to simulate a 6mg/kg dose (peak, 98.6 μ g/mL) and 10mg/kg (141 μ g/mL) every 24 hours (q24h) with pump rate set to achieve a half-life of 8 hours (21, 33). Linezolid was administered to simulate 600mg q12h with a half-life of 6 hours and a peak concentration 21 μ g/mL.(27) Gentamicin was administered to simulate 1.3 mg/kg q12h (approximate: peak 6 μ g/mL, trough 0.4 μ g/mL) a half-life of 2 hours.(24) Rifampin was

- 7 -

administered to simulate a dose of 300mg q8h (approximate peak,14.5 µg/mL) and a half-life
of 4 hours.(24) Additionally, a regimen simulating rifampin 900mg once daily in combination
with linezolid or daptomycin 6mg/kg was performed in duplicate to assess the effects of
rifampin dosage schedule and concentration.

For combination regimen experiments the elimination rate was set for the drug with the shortest half-life, the drug with the longer half-life was supplemented. All model experiments were performed in triplicate unless otherwise noted, to ensure reproducibility. In addition, simulations in the absence of antibiotics were performed at the shortest half-life to assure adequate growth of the organisms in the model.

139 Pharmacodynamic Analysis. Reductions in log₁₀CFU/g over 72 hours were 140 determined by plotting time-kill curves and compared between regimens. Bactericidal activity 141 (99.9% kill) was defined as a \geq 3-log₁₀CFU/g reduction in colony count from the initial 142 inoculum. Bacteriostatic activity was defined as a $< 3 - \log_{10} CFU/g$ reduction in colony count 143 from the initial inoculum while inactive was defined as no observed reductions from initial 144 inoculum. The time to achieve 99.9% kill was determined by non-linear regression (using a minimum of 4 data points) if $r^2 \ge 0.95$, or by visual inspection. Enhancement of activity was 145 146 defined as an increase in kill of $\geq 2 - \log_{10} CFU/g$ by combination of antimicrobials versus the 147 most active single agent of that combination. Improvement was defined as a 1 to 2-log₁₀ 148 CFU/g increase in kill in comparison to the most active single agent, while combinations that 149 result in \geq 1-log₁₀ bacterial growth in comparison to the least-active single agent was 150 considered to represent antagonism. The terms "improvement" and "enhancement" were 151 used because our simulations involve therapeutically obtained serum concentration and this 152 does not permit the mathematical modeling necessary to consider the standard terms 153 "additivity" and "synergy" (34). Indifference was defined as $<1-\log_{10}$ CFU/g change in activity.

- 8 -

Resistance. Development of resistance was evaluated for each monotherapy and combination model at 24, 48, and 72 hours. MIC testing (using Etests) of daptomycin, linezolid, gentamicin and rifampin were conducted with isolates obtained from the 24, 48 and 72 hour time points to identify any MIC shifts. Plates were examined for growth after 24 hours of incubation at 35°C.

159 Pharmacokinetic Analysis. Samples for pharmacokinetic analyses were obtained 160 through the injection port at 0.5, 1, 2, 4, 6, 8, and 24 hours for verification of target antibiotic 161 concentrations. All samples were stored at -80°C until analysis. Daptomycin concentrations 162 were determined by a previously described and validated HPLC method (Center for Anti-163 Infective Research and Development, Hartford, CT) (20). Gentamicin concentrations were 164 determined by a homogeneous particle-enhanced turbidmetric immunoassay (PETIA; 165 Architect, Multigent®; Abbott Diagnostics Abbott Park, IL, USA) at the Providence Veteran Affairs Medical Center. The gentamicin assay was known to have a range of detection of 0.3 166 167 to 10.0 µg/mL and a between day sample precision and percent coefficient of variation (CV%) of 1.35% and < 2.75%, respectively. Linezolid and rifampin concentrations were 168 169 evaluated using HPLC (University of Florida, Gainesville, FL) as previously described (23, 170 24). Only single drug concentrations were evaluated, all in duplicate. The half-lives. 171 maximum concentration (Cmax), and minimum concentration (Cmin) of the antibiotics were 172 determined by the trapezoidal method utilizing PK Analyst software (Version 1.10, MicroMath 173 Scientific Software, Salt Lake City, UT).

In vivo Galleria mellonella survival assay. Efficacy of daptomycin or linezolid in
 enterococcal infection was tested using Galleria mellonella survival assay. Galleria
 mellonella caterpillars at the final-instar stage of development were acquired from the vendor
 (Vanderhorst Wholesale Inc., St. Mary's, OH) and used within 7 days of shipment. All
 experiments were performed according to previously described protocols with minor

-9-

179 modifications (35, 36). Sixteen larvae of appropriate weight (0.25-0.35g) were randomly 180 selected to comprise each group. Larvae were inoculated with either ~4x10⁶ CFU of E. faecalis or 7-9x10⁶ CFU of *E. faecium* followed by tested drug, or PBS as control ~1 hour 181 182 after inoculation. These inocula were chosen after an initial virulence pilot study of these 183 strains, as they were able to kill at least 90% of the larvae within 72h. One group, injected 184 twice with PBS, and one untouched group were used as controls in each experiment. All 185 injections were performed with a volume of 10μ L using a Hamilton syringe. After injection, G. 186 mellonella were incubated at 37 °C and survival was measured daily. Each experiment was 187 repeated at least twice and representative experiments are presented. Any experiment with 188 more than two dead larvae in any control group was discarded. Doses simulated free peak 189 concentrations seen in humans of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid 190 600mg (Table 4). Gentamicin 1.3mg/kg and rifampin 300mg were also tested in combination 191 with either linezolid or daptomycin 6mg/kg.

Statistical Analysis. For the in vitro model, changes in CFU/g at 8, 24, 48, and 72 hours and time to 99.9% kill were compared by two-way analysis of variance with Tukey's Post-Hoc test. Statistical analyses were performed using SPSS Statistical Software (Release 20 SPSS, Inc., Chicago, IL). Survival in the *G. mellonella* model was plotted using Kaplan-Meier curves, and groups were compared using log-rank test (GraphPad Prism 5 software). For all experiments, a p value of \leq 0.05 was considered significant.

- 10 -

198 **RESULTS**

Susceptibility testing. Daptomycin, linezolid, gentamicin, and rifampin MICs for the two strains of enterococci are shown in Table 1. Against *E. faecalis*, there was minimal increase (1 and 2 dilutions respectively) in MICs with daptomycin and linezolid in the presence of high inocula. Against VRE *faecium*, there was an increase in the high inocula MICs of daptomycin and linezolid by 3 dilutions and 2 dilutions, respectively. There was minimal increase (0-2 dilution) in the gentamicin and rifampin MICs when the isolates were evaluated at high inocula. This is consistent with published studies. (10, 23).

In vitro pharmacokinetics and pharmacodynamics. The pharmacokinetic parameters of the antimicrobial agents were within the targeted range and can be found in Table 2. All obtained Cmax values were within 5% of targeted. The average and standard deviation of area under the concentration-time curve (AUC) for daptomycin 6mg/kg was 1028+/-36, daptomycin 10mg/kg was 1430+/-47, and linezolid was 348 +/- 16.

Biofilm production. The *E. faecalis* isolate is a biofilm-positive control and produced consistent biofilm (++) at 24 and 48h. The *E. faecium* isolate did not produce biofilm (0) at 24hours and was weakly adherent (+) at 48 hours.

214 In vitro pharmacodynamic infection model with Simulated Endocardial 215 Vegetations (SEVs). The antimicrobial activity of daptomycin and linezolid were evaluated alone and in combination with gentamicin or rifampin against a high inoculum (10⁹ CFU/g) of 216 217 enterococci in a simulated IE vegetation model (Figure 1). Bactericidal activity (>3 log₁₀ 218 decrease in CFU/g) was achieved by daptomycin 6 and 10mg/kg against E. faecalis at 24h 219 and by daptomycin 10mg/kg against E. faecium at 8h. Linezolid monotherapy did not achieve 220 bactericidal activity against either isolate tested at any time point. The AUC/MIC ratio for 221 daptomycin 6mg/kg was 514-1028 (MIC range 1-2µg/mL), daptomycin 10mg/kg was 715-

- 11 -

1430 (MIC range 1-2µg/mL), and linezolid was 348 (MIC 1µg/mL). Percent time above the
 MIC (%T>MIC) was 100% for daptomycin and linezolid regimens.

224 Against biofilm-forming E. faecalis, daptomycin-containing regimens demonstrated 225 significantly more activity (as measured by a decline in the mean CFU/g) than linezolid-226 containing regimens from 8 hours through the end of the experiment ($p \le 0.005$). (Figure 1a.) 227 Addition of gentamicin significantly increased activity for daptomycin 10mg/kg at 24h (95% CI 228 0.954-3.4029;p=0.033). Addition of gentamicin to daptomycin 6mg/kg was significantly more 229 active than any other regimen tested at 8h ($p \le 0.001$). At 24h, there was a $3\log_{10}$ CFU/g 230 difference in activity between added gentamicin or rifampin to daptomycin 6mg/kg (p=0.010). 231 though the difference was no longer significant at 48h. There was no significant difference 232 between linezolid monotherapy and linezolid plus rifampin or gentamicin regimens at any 233 time point during the 72h experiment, though adding rifampin to linezolid met the definition 234 for improvement at 72h. Changing the schedule of rifampin dosing from 300mg three times 235 daily to 900mg once daily had no effect on either regimen.

236 Against VRE faecium, at 24 and 48h, daptomycin-containing regimens had 237 significantly ($p \le 0.005$) more activity than any of the linezolid-containing regimens (Figure 1b). 238 Addition of gentamicin improved linezolid activity, such that at 72h, linezolid plus gentamicin 239 is only significantly different than daptomycin 6mg/kg (the most active regimen) (95%CI 240 0.0144-3.4556, p=0.047) out of the daptomycin-containing regimens. It was not, however, 241 significantly more active than linezolid monotherapy. The addition of gentamicin was 242 significantly more active than the addition of rifampin with daptomycin 6mg/kg at 24h (95%CI 243 0.2349-2.9984, p=0.013). Rifampin antagonized all regimens at 24h. Addition of rifampin also 244 significantly antagonized linezolid activity at 48 and 72 hours (95%CI 0.0546-3.9921, 245 p=0.040 and 95%CI 0.0595-4.1772, p=0.040). At 72h, activity of linezolid plus rifampin was 246 not significantly different from the growth control. Changing rifampin dosing from three times

- 12 -

daily to once daily did not significantly increase activity, however linezolid plus rifampin once
daily was significantly more active than the growth control at 72h (95%Cl 0.1546-4.6654,
p=0.028).

Gentamicin and rifampin monotherapy did not demonstrate any significant activity against either isolate during the study. Resistance occurred in the rifampin and gentamicin monotherapy models by 24h. The linezolid and daptomycin MICs varied at each time point but never exceeded 4 μ g/mL. In combination with both daptomycin and linezolid, rifampin MICs increased throughout the 72h experiments against VRE, from 4 to >32 μ g/mL. Gentamicin MICs remained constant throughout the combination regimen experiments.

256 In vivo Galleria mellonella survival assay. Results demonstrated that all 257 antimicrobial regimens tested improved survival in all assays (p<0.0001) (Figures 2 and 3). 258 Against E. faecalis, monotherapy only with daptomycin 10mg/kg improved survival 259 significantly over linezolid alone (p=0.0032) (Figure 2a). Gentamicin added efficacy to 260 daptomycin 6mg/kg (p=0.0361), but not to linezolid (Figure 2 c and e), as observed in the in 261 vitro model. Against *E. faecium*, gentamicin added efficacy to both daptomycin 6mg/kg and 262 linezolid regimens (p=0.0009 and 0.0015) (Figure 3c and e). Addition of rifampin was not 263 significant for daptomycin or linezolid against either strain (Figure 2b, d, and 3b, d). Though 264 there was no antagonism observed for rifampin, other results concur with our IVPD findings.

265

- 13 -

266 **DISCUSSION**

Infective endocarditis vegetations often carry a high bacterial burden (10⁸ - 10¹⁰ 267 268 organisms per gram of tissue).(37) This high bacterial density and limited blood supply to this 269 area allow for a diminished immune response and limited antimicrobial drug access. Location 270 of the vegetation (right-sided versus left-sided endocarditis), patient comorbidities, and 271 surgical interventions determine treatment success. (38, 39). The ability of bacteria to form 272 biofilms may contribute to treatment failure, as these bacteria are inherently less susceptible 273 to antibiotics due to decreased growth rates, nutrient restriction, and adaptive stress 274 responses.(40-43)

275 Endocarditis cause by enterococci requires treatment with synergistic antimicrobials; 276 traditionally, a cell wall active agent (beta-lactam or vancomycin) and an aminoglycoside. 277 The presence of high-level resistance to vancomycin eliminates main therapeutic options in 278 the management of serious enterococcal infections. Currently, options for resistant E. 279 faecalis IE include ampicillin in combination with either imipenem/cilastatin or ceftriaxone.(1) 280 While treatment with ampicillin in combination with ceftriaxone is becoming more common 281 against high level aminoglycoside resistant (HLAR) E. faecalis, further investigations into 282 PK/PD activity and dosage are needed. The 2005 American Heart Association Treatment of 283 IE guidelines recommend \geq 8 weeks of linezolid or quinupristin/dalfopristin monotherapy for 284 the treatment of Native or Prosthetic Valve Enterococcal Endocarditis Caused by Strains 285 Resistant to Penicillin, Aminoglycoside, and Vancomycin.(1) In many cases these 286 treatments are not ideal; linezolid has inherent bacteriostatic activity (6, 44), myelosuppression (45, 46), and documented failure in animal studies and human case 287 288 reports in bacteremia and IE. (47-50) Quinupristin/dalfopristin use is also limited as it 289 demonstrates inherent bacteriostatic activity against VRE (51), lack of activity against E. 290 faecalis (6), musculoskeletal toxicities in approximately 50% of the population, and the use of

- 14 -

a central line for administration.(52) Daptomycin is commonly used for the treatment of VRE
 infections (53), although the optimal dose and combinations are unknown.

293 Studies have shown that daptomycin demonstrates activity in enterococcal infections, 294 and may provide an option in patients with allergies or contraindications to other therapies. 295 In a retrospective cohort study of VRE bloodstream infections, treatment with daptomycin or 296 linezolid demonstrated no difference in mortality; however, infection with E. faecium and 297 concurrent treatment with rifampin or gentamicin were independent risk factors for 298 mortality.(54) Antagonistic activity is often observed when rifampin is added to bactericidal 299 agents in high inoculum infections, due to high rates of mutations conferring resistance (~1 in 300 10⁶).(31, 55, 56) The in vitro model demonstrated antagonism with rifampin. The in vivo 301 model used a lower bacterial burden, so antagonism from rifampin resistance may not be as 302 evident. In contrast, previous in vitro studies have shown synergy with daptomycin and rifampin, and non-antagonism with daptomycin and gentamicin.(6) 303

304 G. mellonella is an invertebrate model host that shares many of the advantages of 305 mammalian models while being free of the ethical and logistical constraints that accompany 306 their use.(57) Specifically, G. mellonella larvae can grow in 37 $^{\circ}$ C thus effectively simulating 307 human temperatures and can be directly injected with the tested inoculum and compounds 308 thus allowing for exact quantification of the experimental concentrations. (58) As a result, this 309 model host is well established in the screening of the efficacy and safety of antimicrobial 310 compounds against a variety of infections (59), and has also been effectively used to test 311 antibiotics against Enterococcus spp. in the past. (60) G. mellonella possess both cellular and 312 humoral defenses and have extensive structural and functional similarities to vertebrate 313 immune systems.(61) Finally, G. mellonella larvae have also been proven effective in 314 identifying immunomodulatory properties of several compounds that would have otherwise 315 gone unnoticed in in vitro experiments.(62) Our in vivo model demonstrated improvement

- 15 -

with addition of gentamicin to daptomycin 6mg/kg. It is possible that this improvement would
not be seen with higher daptomycin doses, as survival was 100% at 9 days with the 10mg/kg
dose.

319 Another in vitro model with simulated endocardial vegetations by Hall et al. 320 successfully demonstrated the concentration-dependent activity of daptomycin against VRE, 321 supporting doses >6mg/kg/day, as well as demonstrating daptomycin activity superior to that 322 of linezolid.(32) A recent meta-analysis of VRE bacteremia demonstrated a trend toward 323 increased survival with linezolid treatment over daptomycin.(63) These differences, however, 324 were not statistically significant, and the studies used suffered from problems of different 325 definitions of mortality, low doses of daptomycin (average dose ~6mg/kg), and a possible 326 treatment selection bias in the cohorts.(64) A recent cohort study of patients with gram-327 positive infective endocarditis demonstrated no significant difference in mortality between 328 standard of care antibiotics and daptomycin, given at an average of ~8mg/kg in the E. 329 faecalis group.(65) The E. faecalis group treated with daptomycin had a significantly shorter 330 length of stay compared to standard antibiotics (17.5 [13.5-19.5] vs. 31 [19.0-50.0]days, 331 p=0.02).(65) Although small, this study also demonstrated no significant increase in adverse 332 events with higher dose daptomycin. Our work demonstrates no statistically significant 333 differences in any daptomycin regimen at 72h. High-dose daptomycin has some in vitro 334 evidence to support its use in complicated enterococcal bacteremia and IE, as 10mg/kg, but 335 not 6mg/kg, can prevent MIC increases in daptomycin non-susceptible S. aureus 336 isolates.(66)

In conclusion, daptomycin-containing regimens generally were more active against enterococcal isolates than linezolid throughout the experiments. The addition of rifampin to either linezolid or daptomycin did not significantly increase antibacterial activity in an in vitro sequestered high inoculum model of enterococcal endocarditis at 72h, and rifampin delayed

- 16 -

341 the bactericidal activity of daptomycin during the first 24 hours. The inhibition of bacterial 342 RNA synthesis may be responsible for delaying the killing activities of cell wall active 343 agents.(67) The addition of gentamicin improved the bactericidal activity of daptomycin most 344 in the first 24h against E. faecalis, and increased linezolid activity at 72h against VRE 345 faecium. It is currently unclear how linezolid, a protein synthesis inhibitor, demonstrates 346 improved activity in the presence of gentamicin. This improved activity has also been 347 observed in S. aureus and a vancomycin-resistant E. faecalis.(67-69) We feel that our work 348 supports the use of daptomycin 6 or 10mg/kg with 24 hours of gentamicin added for E. 349 faecalis, as the most active therapy for enterococcal endocarditis. Other clinical studies 350 demonstrate worse clinical outcomes when using rifampin in combination, while gentamicin 351 adds activity in the first 24 hours only, and should be limited due to concerns for 352 nephrotoxicity.

353 A limitation of this study is the use of limited isolates. In addition, we cannot conclude 354 that our in vitro results will hold true with treatment durations longer than 72 hours. Our 355 findings with daptomycin and linezolid monotherapy are consistent with published clinical, in 356 vitro and animal models. (7, 32, 70) The linezolid concentration in *G. mellonella*, while active, 357 was lower than desired due to limits on available pharmaceutical concentrations. It is 358 possible that the differences seen would not be significant if a higher concentration were 359 used. While G. mellonella received doses targeting the free peak concentration achieved in 360 humans, each drug was dosed only once, with survival being measured over 9 days, and 361 pharmacokinetic information including metabolism and excretion are unknown.

The results support daptomycin 6 or 10mg/kg, with gentamicin added for 24 hours, against enterococci in simulated endocardial vegetations. Nonetheless, our results should be applied to clinical practice with caution. Confirmation of these results in clinical studies is needed before these regimens can be adopted for use in the care of patients.

366

367

ACKNOWLEDGEMENTS

368 We thank Kayla Babcock for laboratory assistance. We gratefully acknowledge Christine 369 Long, Core Laboratory Supervisor and Clyde Belgrave M.D., Chief of Laboratory Services at 370 the Veterans Affairs Medical Center in Providence RI, for analysis of the gentamicin samples. 371 We also gratefully acknowledge David P. Nicolau, Pharm.D., FCCP and Christina Sutherland 372 at the Center for Anti-Infective Research and Development at Hartford Hospital (Hartford, 373 CT) for HPLC analysis of daptomycin concentrations and Charles Peloguin, Pharm.D. from 374 University of Florida (Gainesville, FL) for HPLC analysis of the linezolid and rifampin 375 samples.

376

377 Conflicts of Interest and Disclosures

The views expressed are those of the authors and do not necessarily reflect the position or policy of the United States Department of Veterans Affairs. All data collection, extraction, and analyses were carried out by the Department of Veterans Affairs study team. This research was funded in part by Cubist Pharmaceuticals. MKL: Cubist and Pfizer research funding. KLL: Cubist, Astellas, Theravance, Forest, Davol, Marvao, and Pfizer research funding, advisor, speaker, and/or consultancy.

REFERENCES

- Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr., Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-434.
- Martinez-Marcos FJ, Lomas-Cabezas JM, Hidalgo-Tenorio C, de la Torre-Lima J, Plata-Ciezar A, Reguera-Iglesias JM, Ruiz-Morales J, Marquez-Solero M, Galvez-Acebal J, de Alarcon-Gonzalez A. 2009. [Enterococcal endocarditis: a multicenter study of 76 cases]. Enferm Infecc Microbiol Clin 27:571-579.
- Mohamed JA, Huang DB. 2007. Biofilm formation by enterococci. J Med Microbiol 56:1581-1588.
- Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
- Biedenbach DJ, Moet GJ, Jones RN. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 50:59-69.
- 6. **Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP.** 2010. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother **65:**1126-1136.
- Cervera C, Castaneda X, Pericas JM, Del Rio A, de la Maria CG, Mestres C, Falces C, Marco F, Moreno A, Miro JM. 2011. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int J Antimicrob Agents 38:365-370.
- 8. **Steenbergen JN, Alder J, Thorne GM, Tally FP.** 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother **55:**283-288.
- Caron F, Kitzis MD, Gutmann L, Cremieux AC, Maziere B, Vallois JM, Saleh-Mghir A,
 Lemeland JF, Carbon C. 1992. Daptomycin or teicoplanin in combination with gentamicin for

treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother **36**:2611-2616.

- DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. 2006. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 50:3529-3534.
- 11. **Kanafani ZA, Federspiel JJ, Fowler VG, Jr.** 2007. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis **39**:75-77.
- 12. **Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS.** 1992. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother **36**:1864-1869.
- Snydman DR, McDermott LA, Jacobus NV. 2005. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother 17:614-621.
- 14. **Barber GR, Lauretta J, Saez R.** 2007. A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy **27:**927-932.
- 15. **Das SS, Anderson JR, Macdonald AA, Somerville KW.** 1994. Endocarditis due to high level gentamicin resistant Enterococcus faecium. J Infect **28**:185-191.
- 16. **Rand KH, Houck HJ, Silverman JA.** 2007. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother **59**:1017-1020.
- 17. **Cilli F, Aydemir S, Tunger A.** 2006. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother **18:**27-32.
- 18. **Rand KH, Houck H.** 2004. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother **53**:530-532.
- Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. 2009. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 43:1211-1219.
- 20. **Akins RL, Rybak MJ.** 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant

Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother **45**:454-459.

- 21. **Benvenuto M, Benziger DP, Yankelev S, Vigliani G.** 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother **50**:3245-3249.
- 22. Hershberger E, Coyle EA, Kaatz GW, Zervos MJ, Rybak MJ. 2000. Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. **44**:1921-1924.
- 23. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother **48**:4665-4672.
- 24. LaPlante KL, Woodmansee S. 2009. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 53:3880-3886.
- LaPlante KL, Mermel LA. 2007. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 22:2239-2246.
- Pillai SK, Sakoulas G, Eliopoulos GM, Moellering RC, Jr., Murray BE, Inouye RT. 2004.
 Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis. J Infect Dis 190:967-970.
- Institute CaLS. 2012. 2012 Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – ninth edition, M07-A9CLSI, Wayne, PA.
- Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH. 1985. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996-1006.

- 29. Qin X, Singh KV, Weinstock GM, Murray BE. 2001. Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J Bacteriol **183**:3372-3382.
- 30. **Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M.** 2000. A modified microtiterplate test for quantification of staphylococcal biofilm formation. J Microbiol Methods **40**:175-179.
- 31. **Rose WE, Leonard SN, Rybak MJ.** 2008. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother **52**:3061-3067.
- 32. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. 2012. Evaluation of standard- and highdose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 56:3174-3180.
- Vouillamoz J, Moreillon P, Giddey M, Entenza JM. 2006. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58:1208-1214.
- Allen GP, Cha R, Rybak MJ. 2002. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46:2606-2612.
- 35. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr., Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother **53**:2605-2609.
- 36. **Fuchs BB, O'Brien E, Khoury JB, Mylonakis E.** 2010. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence **1**:475-482.
- 37. **Bayer AS, Norman DC.** 1990. Valve site-specific pathogenetic differences between right-sided and left-sided bacterial endocarditis. Chest **98**:200-205.
- 38. Fowler VG, Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E,

Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. Jama **293**:3012-3021.

- 39. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665.
- 40. Gotz F. 2002. Staphylococcus and biofilms. Mol Microbiol 43:1367-1378.
- 41. **Donlan RM, Costerton JW.** 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev **15**:167-193.
- 42. **Brown MR, Allison DG, Gilbert P.** 1988. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J Antimicrob Chemother **22**:777-780.
- Xu KD, McFeters GA, Stewart PS. 2000. Biofilm resistance to antimicrobial agents. Microbiology 146 (Pt 3):547-549.
- Irinoda K, Nomura S, Hashimoto M. 2002. [Antimicrobial and clinical effect of linezolid (ZYVOX), new class of synthetic antibacterial drug]. Nippon Yakurigaku Zasshi 120:245-252.
- French G. 2003. Safety and tolerability of linezolid. J Antimicrob Chemother 51 Suppl 2:ii45-53.
- 46. **Green SL, Maddox JC, Huttenbach ED.** 2001. Linezolid and reversible myelosuppression. Jama **285:**1291.
- 47. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Hamel A, Bugnon D, Ge JY, Potel G. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycinintermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother **51**:3397-3400.
- 48. **Rouse MS, Steckelberg JM, Patel R.** 2007. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis **58**:363-365.

- 49. **Ruiz ME, Guerrero IC, Tuazon CU.** 2002. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis **35**:1018-1020.
- 50. **Zimmer SM, Caliendo AM, Thigpen MC, Somani J.** 2003. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis **37**:e29-30.
- 51. Linden PK. 2002. Treatment options for vancomycin-resistant enterococcal infections. Drugs 62:425-441.
- 52. Linden PK, Moellering RC, Jr., Wood CA, Rehm SJ, Flaherty J, Bompart F, Talbot GH. 2001. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis **33**:1816-1823.
- 53. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol **10**:266-278.
- 54. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J. 2010. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther 32:1713-1719.
- 55. Murillo O, Pachon ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F, Ariza J. 2008. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob Agents Chemother 52:3681-3686.
- 56. **Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG**. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med **168**:805-819.
- 57. Arvanitis M, Glavis-Bloom J, Mylonakis E. 2013. Invertebrate models of fungal infection. Biochim Biophys Acta **1832**:1378-1383.
- 58. Glavis-Bloom J, Muhammed M, Mylonakis E. 2012. Of model hosts and man: using Caenorhabditis elegans, Drosophila melanogaster and Galleria mellonella as model hosts for infectious disease research. Adv Exp Med Biol 710:11-17.

- Desbois AP, Coote PJ. 2012. Utility of Greater Wax Moth Larva (Galleria mellonella) for Evaluating the Toxicity and Efficacy of New Antimicrobial Agents. Adv Appl Microbiol 78:25-53.
- 60. III INVALID CITATION III
- 61. **Cook SM, McArthur JD.** 2013. Developing Galleria mellonella as a model host for human pathogens. Virulence **4**:350-353.
- Kelly J, Kavanagh K. 2011. Caspofungin primes the immune response of the larvae of Galleria mellonella and induces a non-specific antimicrobial response. J Med Microbiol 60:189-196.
- 63. Whang DW, Miller LG, Partain NM, McKinnell JA. 2013. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother **57**:5013-5018.
- Shukla BS, Gauthier TP, Correa R, Smith L, Abbo L. 2013. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. Int J Clin Pharm 35:697-703.
- 65. Carugati M, Bayer AS, Miro JM, Park LP, Guimaraes AC, Skoutelis A, Fortes CQ, Durante-Mangoni E, Hannan MM, Nacinovich F, Fernandez-Hidalgo N, Grossi P, Tan RS, Holland T, Fowler VG, Jr., Corey RG, Chu VH. 2013. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother 57:6213-6222.
- 66. **Gould IM, Miro JM, Rybak MJ.** 2013. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents **42**:202-210.
- 67. **Grohs P, Kitzis MD, Gutmann L.** 2003. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother **47:**418-420.
- 68. Wareham DW, Abbas H, Karcher AM, Das SS. 2006. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect **52**:300-304.
- 69. Jacqueline C, Asseray N, Batard E, Le Mabecque V, Kergueris MF, Dube L, Bugnon D, Potel G, Caillon J. 2004. In vivo efficacy of linezolid in combination with gentamicin for the treatment

of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents **24**:393-396.

70. **Levine DP.** 2008. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother **62 Suppl 3:**iii35-39.

	MIC in mg/L ^a			
Antimicrobial	E. faecalis	E. faecium		
	ATCC 29212	L2001		
Daptomycin	2 (4)	1 (8)		
Linezolid	1 (4)	1 (4)		
Gentamicin	16 (32)	16 (32)		
Rifampin	0.5 (0.5)	4 (16)		
Vancomycin	2	>256		

TABLE 1. MIC results using standard and high inocula for enterococcal isolates. ^{*a*} The standard inoculum was 5x10⁵ CFU/mL, and the high inoculum was 5x10⁹ CFU/mL. Data for the high inoculum are presented parenthetically.

NA = not applicable

Regimen ^a	Peak concentration (mg/L)		Half-life (h)		
	Targeted	Obtained	Targeted	Obtained	
Daptomycin 6mg/kg q24h	98.6	102.5 ± 1.96	8	7.92 ± 0.18	
Daptomycin 10mg/kg q24h	140.0	143.2 ± 1.94	8	7.87 ± 0.21	
Linezolid 600mg q12h	21.0	21.9 ± 0.86	6	6.52 ± 0.87	
Gentamicin 1.3mg/kg q12h	6.0	5.7 ± 0.51	2	2.08 ± 0.17	
Rifampin 300mg q8h	10.5	11.0 ± 1.23	4	3.60 ± 0.50	

TABLE 2. Values of mean targeted and obtained pharmacokinetic parameters obtained with simulated endocarditis vegetations (SEV) infection models ± standard deviation ^abased on a 75 kg patient

TABLE 3. Inoculum change from starting inoculum of 5×10^9 CFU/g at 8, 24, and 72 h obtained in the SEV model. Note that positive values indicate growth.

^a Indicates statistically significant difference from growth control.

Antimicrobial	E. faecalis		E. faecium			
	8h	24h	72h	8h	24h	72h
Growth Control	+1.13	+1.06	+1.29	+1.82	+1.93	+1.86
Daptomycin 6mg/kg	-2.07 ^a	-4.28 ^a	-5.07 ^a	-2.11 ^a	-4.56 ^a	-5.86 ^a
Daptomycin 6mg/kg+ rifampin	-1.88 ^a	-2.99 ^a	-5.13 ^a	-1.84 ^a	-3.33 ^a	-5.30 ^a
Daptomycin 6mg/kg + gentamicin	-4.36 ^a	-6.02 ^a	-6.15 ^a	-2.38 ^a	-4.96 ^a	-5.05 ^a
Daptomycin 10mg/kg	-2.23 ^a	-4.17 ^a	-6.07 ^a	-3.57 ^a	-4.90 ^a	-5.63 ^a
Daptomycin 10mg/kg + rifampin	-1.65 ^a	-3.48 ^a	-5.46 ^a	-2.09 ^a	-3.71 ^a	-5.41 ^a
Daptomycin 10mg/kg + gentamicin	-2.32 ^a	-6.07 ^a	-5.67 ^a	-2.99 ^a	-4.08 ^a	-5.04 ^a
Linezolid	+0.02	-0.19	-0.95	+0.07	-1.08 ^a	-2.90 ^a
Linezolid + rifampin	-0.07	-0.40	-1.96 ^a	+0.45	+0.48	-0.79
Linezolid + gentamicin	+0.13	-0.15	-0.88 ^a	-0.14	-0.67 ^a	-4.08 ^a

Mean change in bacterial density (log₁₀ CFU/g)




Figure 1. The activity (change in log₁₀ CFU/g) of daptomycin- or linezolid- containing regimens against a) *Enterococcus faecalis*. (vancomycin- susceptible, gentamicin- susceptible, rifampin- susceptible, daptomycin- susceptible, linezolid- susceptible) or b) *Enterococcus faecium* (vancomycin- resistant, gentamicin- susceptible, rifampin- resistant, daptomycin- susceptible, linezolid- susceptible, linezolid- susceptible).




Figure 3. Efficacy of compounds against *E. faecalis* on a *G. mellonella* infection model. Each line on the graph represents the survival of a group of 16 larvae injected with *E. faecalis* followed by injection of the relative drug.

Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg alone and in combination with rifampin c) daptomycin 6mg/kg alone or in combination with gentamicin d) linezolid alone or in combination with rifampin and e) linezolid alone or in combination with gentamicin.




Figure 4. Efficacy of compounds against *E. faecium* on a *G. mellonella* infection model. Each line on the graph represents the survival of a group of 16 larvae injected with *E. faecium* followed by injection of the relative drug. Survival proportion with a) monotherapy of daptomycin 6mg/kg, daptomycin 10mg/kg, or linezolid vs controls. b) daptomycin 6mg/kg alone and in combination with rifampin c) daptomycin 6mg/kg alone or in combination with gentamicin d) linezolid alone or in combination with rifampin and e) linezolid alone or in combination with gentamicin.

Antimicrobial and	Targeted free peak	Administered concentration
Human Dose	concentration (mg/L)	in <i>G. mellonella</i> (mg/L)
Daptomycin 6mg/kg	9.8	9.15
Daptomycin 10mg/kg	14.0	13.07
Linezolid 600mg	14.0	8.00 ^a
Gentamicin 1.3mg/kg	6.0	5.60
Rifampin 300mg	2.6	2.50

Table 4. Targeted vs. administered peak concentrations in *G. mellonella* models. ^a Linezolid concentrations were lower than targeted due to limits on the available pharmaceutical concentrations.